A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults With Partial-Onset Seizures (Extension of Study RGB113905)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Retigabine (Primary) ; Antiepileptic drugs
- Indications Complex partial epilepsy; Partial epilepsies
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 04 Aug 2017 Planned End Date changed from 1 Sep 2017 to 28 Aug 2017.
- 24 May 2017 This trial has been completed in Poland.
- 12 Jan 2017 Planned End Date changed from 1 Dec 2020 to 1 Sep 2017.